Clinical Trial Update: Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant radiochemotherapy combined with panitumumab in locally advanced KRAS wild-type rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: National Center for Tumor Diseases, Heidelberg | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED